{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:34:22Z","timestamp":1791012862617,"version":"4.1.0"},"reference-count":106,"publisher":"Informa UK Limited","issue":"11","funder":[{"name":"Swiss Science Research Foundation grants","award":["PBLAP3-129427\/1"],"award-info":[{"award-number":["PBLAP3-129427\/1"]}]},{"DOI":"10.13039\/100005565","name":"Centocor","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007110","name":"Schering-Plough","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007110","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016879","name":"Union Chimique Belge","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016879","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Abbott"},{"name":"Genentech"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007013","name":"Hoffmann\u2013La Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol Myers Squibb"},{"name":"Millenium Pharmaceuticals"},{"name":"Tillotts"},{"name":"GlaxoSmithKline"},{"name":"ChemoCentryx"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.2217\/imt.11.122","type":"journal-article","created":{"date-parts":[[2011,11,4]],"date-time":"2011-11-04T16:33:59Z","timestamp":1320424439000},"page":"1341-1352","source":"Crossref","is-referenced-by-count":68,"title":["Cytokine Blockade in Inflammatory Bowel Diseases"],"prefix":"10.1080","volume":"3","author":[{"given":"Cl\u00e9mentine","family":"Perrier","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, University Hospital, Catholic University Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rutgeerts","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University Hospital, Catholic University Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2011,11,4]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-030409-101225"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.206466"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20091233"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2011.01.002"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.199679"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2009.05.016"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1823"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3181dd4fa5"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.60.051407.123757"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.012"},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.01.002"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21304"},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.10.51"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2005.00218.x"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371502"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.06.064"},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.02.001"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28674"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.04.022"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.035253"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.10.001"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.53.1.70"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.2.206"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28702"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200822050-00005"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.10.008"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02786.x"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.114660"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.2174\/138945010790309867"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.9"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.236869"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.406"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00238-1"},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.06.025"},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50145"},{"issue":"11","key":"e_1_3_2_3_38_1","first-page":"1212","volume":"10","author":"Van Bockstaele F","year":"2009","unstructured":"Van Bockstaele F , HolzJB, RevetsH. The development of nanobodies for therapeutic applications. Curr. Opin Investig. Drugs10(11) , 1212\u20131224 (2009).","journal-title":"Curr. Opin Investig. Drugs"},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1166"},{"key":"e_1_3_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2011.566856"},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1057"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.05067.x"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2010.09.062"},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i35.5606"},{"key":"e_1_3_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0107-26"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07499-8"},{"key":"e_1_3_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.116467"},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.07.014"},{"key":"e_1_3_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033402"},{"key":"e_1_3_2_3_50_1","unstructured":"Panaccione R GamelliA SandbornW et al. Briakinumab (ABT874) for treatment of Crohn\u2018s diseas (CD). UEGW Vienna Austria (2010)."},{"key":"e_1_3_2_3_51_1","unstructured":"Sandborn W GasinkC GaoL et al. A multicenter randomized double-blind placebo-controlled Phase 2b study of ustekinumab a human monoclonal antibody to IL-12\/23 p40 in patients with moderately to severely active Crohn\u2018s disease: results through week 22 from the Certifi trial. Presented at: Digestive Disease Week. Chicago IL USA 7\u201310 May 2011."},{"key":"e_1_3_2_3_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ibd.0000225337.14356.31"},{"key":"e_1_3_2_3_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21159"},{"key":"e_1_3_2_3_54_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1994.14.235"},{"key":"e_1_3_2_3_55_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.157.3.1261"},{"key":"e_1_3_2_3_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21038"},{"key":"e_1_3_2_3_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.079434"},{"issue":"4","key":"e_1_3_2_3_58_1","first-page":"431","volume":"13","author":"Colpaert S","year":"2002","unstructured":"Colpaert S , VastraelenK, LiuZ et al. In vitro analysis of interferon \u03b3 (IFN-\u03b3) and interleukin-12 (IL-12) production and their effects in ileal Crohn\u2018s disease. Eur. Cytokine Netw.13(4) , 431\u2013437 (2002).","journal-title":"Eur. Cytokine Netw."},{"key":"e_1_3_2_3_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.205443"},{"key":"e_1_3_2_3_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxq030"},{"key":"e_1_3_2_3_61_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.99-1003rev"},{"key":"e_1_3_2_3_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.36.1.45"},{"key":"e_1_3_2_3_63_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.1999.01989.x"},{"key":"e_1_3_2_3_64_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.01.012"},{"key":"e_1_3_2_3_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00697.x"},{"key":"e_1_3_2_3_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199702000-00012"},{"issue":"8","key":"e_1_3_2_3_67_1","first-page":"1301","volume":"90","author":"Nielsen OH","year":"1995","unstructured":"Nielsen OH , CiardelliT, WuZ, LangholzE, KirmanI. Circulating soluble interleukin-2 receptor\u03b1 and \u03b2 chain in inflammatory bowel disease. Am. J. Gastroenterol.90(8) , 1301\u20131306 (1995).","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_3_2_3_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(02)05907-5"},{"key":"e_1_3_2_3_69_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.089854"},{"key":"e_1_3_2_3_70_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01639.x"},{"key":"e_1_3_2_3_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02904.x"},{"key":"e_1_3_2_3_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2711"},{"key":"e_1_3_2_3_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)80068-P"},{"key":"e_1_3_2_3_74_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v113.pm9247454"},{"key":"e_1_3_2_3_75_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.20196"},{"key":"e_1_3_2_3_76_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.20229"},{"key":"e_1_3_2_3_77_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.1.42"},{"key":"e_1_3_2_3_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.03.028"},{"key":"e_1_3_2_3_79_1","doi-asserted-by":"crossref","unstructured":"Vermeire S RutgeertsP D\u2018haensG et al. A Phase 2a Randomized placebo-controlled double-blind multi-center dose escalation study to evaluate the safety tolerability pharmacodynamics and efficacy of AG011 in patients with moderately active ulcerative colitis. Presented at: Digestive Disease Week. New Orleans LA USA 1\u20135 May 2010.","DOI":"10.1016\/S0016-5085(10)60041-8"},{"key":"e_1_3_2_3_80_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.159.11.5661"},{"key":"e_1_3_2_3_81_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M312757200"},{"key":"e_1_3_2_3_82_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0410226"},{"key":"e_1_3_2_3_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02087911"},{"issue":"12","key":"e_1_3_2_3_84_1","first-page":"1503","volume":"78","author":"Peterson RL","year":"1998","unstructured":"Peterson RL , WangL, AlbertL, KeithJC Jr, Dorner AJ. Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab. Invest.78(12) , 1503\u20131512 (1998).","journal-title":"Lab. Invest."},{"key":"e_1_3_2_3_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70550-0"},{"key":"e_1_3_2_3_86_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01179.x"},{"key":"e_1_3_2_3_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.00356.x"},{"key":"e_1_3_2_3_88_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012952"},{"key":"e_1_3_2_3_89_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.178665"},{"key":"e_1_3_2_3_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21301"},{"key":"e_1_3_2_3_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_3_2_3_92_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_3_2_3_93_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_3_2_3_94_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.106781"},{"key":"e_1_3_2_3_95_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2011.541435"},{"key":"e_1_3_2_3_96_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067594"},{"key":"e_1_3_2_3_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02791.x"},{"key":"e_1_3_2_3_98_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00251.x"},{"key":"e_1_3_2_3_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.05070.x"},{"key":"e_1_3_2_3_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.454"},{"key":"e_1_3_2_4_2_1","unstructured":"A study of the safety and effectiveness of CNTO 148 (golimumab) in patients with moderately to severely active ulcerative colitis (CR014176) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00487539?term=Golimumab&rank=7"},{"key":"e_1_3_2_4_3_1","unstructured":"Phase I study of safety and biological effects of C326 an inhibitor of IL-6 in Crohn\u2018s disease http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00353756?term=avimer&rank=1"},{"key":"e_1_3_2_4_4_1","doi-asserted-by":"crossref","unstructured":"Vandepapeliere P Malan F Rogler G et al. Phase I\u2013II safety immunogenicity and clinical results of TNF\u03b1-kinoid immunotherapeutic immunization in Crohn\u2018s disease patients. ECCO(2011) www.neovacs.fr\/files\/Presentation_ECCO_2011.pdf","DOI":"10.1016\/S0016-5085(11)60501-5"},{"key":"e_1_3_2_4_5_1","unstructured":"Hueber W Sands B Vandemeulebroecke M et al. Inhibition of IL-17A by secukinumab is ineffective for Crohn\u2018s disease (CD). ECCO(2011) Link"},{"key":"e_1_3_2_4_6_1","unstructured":"A study to assess efficacy safety and tolerability of the anti-IL-13 monoclonal antibody QAX576 in the treatment of perinanal fistulas in patients suffering from Crohn\u2018s disease http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01316601?term=IL-13&rank=16"},{"key":"e_1_3_2_4_7_1","unstructured":"Basiliximab maintenance in ulcerative colitis http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01061996?term=basiliximab+ulcerative+colitis&rank=1"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt.11.122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T15:09:50Z","timestamp":1715958590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt.11.122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":106,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.2217\/imt.11.122"],"URL":"https:\/\/doi.org\/10.2217\/imt.11.122","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}